In patients with hormone receptor-positive (HR + ) BC patients, traditional endocrine therapy has already improved the long-term survival of this population, including basic endocrine drugs such as tamoxifen, aromatase inhibitors, fulvestrant, and etc [11–13]. Here, NR4A1 is linked to breast cancer.